Bactobio

Transforming microbial discoveries into high-value products with real-world potential

Bactobio uses AI, DNA sequencing, and synthetic biology to discover microbial species and antimicrobials with its Fleming platform.

Bactobio employs DNA sequencing, machine learning, and synthetic biology to culture novel microbes.

Bactobio discusses antimicrobial resistance challenges and its antibiotic development during 2023 World Antimicrobial Awareness Week.

Bactobio's first intern in the Compound Discovery team.

Soil microbes: powering the future of antimicrobial discovery

Bactobio partners with the DOE Joint Genome Institute to create a dataset for AI-driven chemical discovery.

Bactobio announces discovery of a novel antibiotic compound active against drug-resistant Acinetobacter baumannii and other dangerous bacterial pathogens.

Bactobio identifies two bio-derived compounds that protect wheat against Septoria wheat blotch, including resistant strains, without harming plants.

Bactobio is named one of LinkedIn’s Top 20 UK Startups of 2024 for its innovative science and impact-driven team.

​Join Bactobio's dynamic team of brilliant scientists and be part of groundbreaking research at the forefront of biotechnology.

Jamie Lee at Bactobio uses data science to explore microbes for novel antimicrobial production.

Laboratory Scientist All

Bactobio’s mission is to create a safer, greener world by extracting metabolites from microbial dark matter.

Bactobio outlines data security and privacy measures in its privacy policy.

Bactobio provides terms of use for interactions with its biotech content.

GitHubRepository owner

Bactobio collaborates with the **DOE’s Joint Genome Institute (JGI)** to explore microbial molecules. The JGI will sequence **nearly 5,000 transcriptomes from 80 bacterial species**, while Bactobio leads **metabolomic analyses** of the samples. The partnership aims to uncover novel compounds from bacterial metabolism for potential applications in biotechnology.

Oct 2026genomeweb.comNews article

Bactobio Ltd. secures an oversubscribed £6 million bridge financing round to advance its research into new antimicrobial compounds. The U.K.-based biotech company leverages the funds to expand its pipeline of potential treatments targeting antibiotic-resistant infections. The round reflects growing investor interest in antimicrobial innovation amid rising global health challenges.

Dec 2022Labiotech.euNews article

Bactobio secures **$3.8 million** in seed funding to advance its biotech research. The company, formerly named **Baccuico**, rebrands under the new name **Bactobio** as it scales operations in London. Investors back the venture’s focus on microbial-based solutions, though specific applications remain unstated.

Oct 2021Business WireNews article